|
The service visit at the university of washington medical center was scheduled per capa(b)(4) within work order wo-00199657.During the site visit, the hybridization (hyb) heater required recalibration due to failing initial verification at setpoint 2.Field quality updated risk assessment question 2 to 'yes' since the setpoint temperature failed outside the accepted limits established by the verigene i assay temperature tolerance guard band risk report (03838).Data review per the verigene assay temperature tolerance (guard-band) study report (03768),the study evaluated assay performance of verigene® rp flex, ep, cdf, bc-gp and bc-gn assays at varying critical temperature parameters and established a functional range of temperature for assay tolerance above and below the nominal set points.It was determined within 03838, that the hyb heater has an upper and lower tolerance of +/-2 degree celsius from the setpoint temperature 1 (38.5c) and setpoint 2 (90.0c).In reviewing the attached naplogs, setpoint 1 for the hyb heater was within the acceptable temperature range verification testing.Per the verigene processor sp system design fmea (napiii-fmea-1729), the system will monitor temperature throughout the procedure.Once at temperature, the system must maintain the target temperature within +/- 1c, or the system will alarm and terminate the procedure via the hardware/software.However, setpoint 2 had an adjusted temperature of +87.4c, 0.6c lower than the acceptable range per 03838.Due the finding, risk assessment question 2 was updated to yes.Site performance: the customer site is currently running the bc-gp verigene assay.The hyb heater verification failure can potentially impact assay performance related to the bc-gp assay per 03838.Within an 18-month timeframe from the verification failure, the customer site has not reported any patient sample false results on either assay.Conclusion: the customer site reported no false results for the sp processor s/n (b)(4) there is no indication of this verification failure resulting in an adverse effect to patient results.
|